Dye solutions based on Lutein and Zeaxanthin: In vitro and in vivo analysis of ocular toxicity profiles

Current Eye Research

Volumn 40, Issue 7, 2015, Pages 707-718

  Casaroli Marano, Ricardo P ^a,b,c   Sousa Martins, Diogo ^a   Martínez Conesa, Eva M ^c   Badaró, Emmerson ^a   Nunes, Renata Portella ^a   Lima Filho, Acácio As ^a   Rodrigues, Eduardo B ^a   Belfort, Rubens ^a   Maia, Maurício ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

ARPE 19; Chromovitrectomy; in vitro validation assays; Lutein; Retinal pigment epithelium; Zeaxanthin

Indexed keywords

BRILLIANT BLUE; DYE; TRYPAN BLUE; UNCLASSIFIED DRUG; XANTHOPHYLL; XANTHOPHYLL DYE SOLUTION; ZEAXANTHIN; ZEAXANTHIN DYE SOLUTION; BENZENESULFONIC ACID DERIVATIVE; COLORING AGENT; DRUG COMBINATION;

A WAVE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B WAVE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY ASSAY; ELECTRORETINOGRAM; ELECTRORETINOGRAPHY; EPITHELIUM CELL; EYE TOXICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RABBIT; TRANSMISSION ELECTRON MICROSCOPY; WST-1 ASSAY; ANIMAL; CELL LINE; CORNEA EPITHELIUM; DRUG COMBINATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; INTRAVITREAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; PIGMENT EPITHELIUM; RETINA; ULTRASTRUCTURE;

ANIMALS; BENZENESULFONATES; CELL LINE; COLORING AGENTS; DRUG COMBINATIONS; ELECTRORETINOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIUM, CORNEAL; HUMANS; INTRAVITREAL INJECTIONS; LUTEIN; MICROSCOPY, ELECTRON, TRANSMISSION; RABBITS; RETINA; RETINAL PIGMENT EPITHELIUM; TRYPAN BLUE; ZEAXANTHINS;

EID: 84930703080     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2014.952831     Document Type: Article

References (39)

1. Rodrigues EB, Penha FM, Furlani B, Meyer CH, Maia M, Farah ME. Historical aspects and evolution of the application of vital dyes in vitreoretinal surgery and chromovitrectomy. Dev Ophthalmol 2008;42:29-34.
2. Farah ME, Maia M, Rodriguez EB. Dyes in Ocular Surgery: principles for use in chromovitrectomy. Am J Ophthalmol 2009;148:332-340.
3. Da Mata AP, Burk SE, Foster RE, Riemann CD, Petersen MR, Nehemy M, et al. Long-term follow-up of indocyanine green-assisted peeling of the retinal internal limiting membrane during vitrectomy surgery for idiopathic macular hole repair. Ophthalmology 2004;111:2246-2253.
4. Farah ME, Maia M, Penha FM. The use of vital dyes during vitreoretinal surgery - chromovitrectomy. In: Nguyen QD, Rodrigues EB, Farah ME, Mieler WF, eds. Retinal pharmacotherapy. Philadelphia, PA: Saunders Co; 2010. pp 331-335.
5. Rodrigues EB, Maia M, Meyer CH, Penha FM, Dib E, Farah ME. Vital dyes for chromovitrectomy. Curr Opin Ophthalmol 2007;18:179-187.
6. Rodrigues EB, Costa EF, Penha FM, Melo GB, Botto?s J, Dib E, et al. The use of vital dyes in ocular surgery. Surv Ophthalmol 2009;54:576-617.
7. Rodrigues EB, Penha FM, de Paula Fiod Costa E, Maia M, Dib E, Moraes Jr M, et al. Ability of new vital dyes to stain intraocular membranes and tissues in ocular surgery. Am J Ophthalmol 2010;149:265-277.
8. Enaida H, Ishibashi T. Brilliant blue in vitreoretinal surgery. Dev Ophthalmol 2008;42:115-125.
9. Enaida H, Hisatomi T, Hata Y, Ueno A, Goto Y, Yamada T, et al. Brilliant blue G selectively stains the internal limiting membrane/brilliant blue G-assisted membrane peeling. Retina 2006;26:631-636.
10. Yuen D, Gonder J, Proulx A, Liu H, Hutnik C. Comparison of the in vitro safety of intraocular dyes using two retinal cell lines: a focus on brilliant blue G and indocyanine green. Am J Ophthalmol 2009;147:251-259.
11. Maia M, Haller JA, Pieramici DJ, Margalit E, de Juan Jr E, Farah ME, et al. Retinal pigment epithelium abnormalities after intravitreal injection of ICG to aid peeling of the internal limiting membrane in human eyes. Retina 2004;24: 157-160.
12. Maia M, Margalit E, Lakhanpal R, Tso MO, Grebe R, Torres G, et al. Effects of intravitreal indocyanine green injection in rabbits. Retina 2004;24:69-79.
13. Rodrigues EB, Penha FM, Farah ME, de Paula Fiod Costa E, Maia M, Dib E, et al. Preclinical investigation of the retinal biocompatibility of six novel vital dyes for chromovitrectomy. Retina 2009;29:497-510.
14. Yemelyanov AY, Katz NB, Bernstein PS. Ligand-binding characterization of xanthophyll carotenoids to solubilized membrane proteins derived from human retina. Exp Eye Res 2001;72:381-392.
15. Ahmed SS, Lott MN, Marcus DM. The macular xanthophylls. Surv Ophthalmol 2005;50:183-193.
16. Nolan JM, Stack J, Mellerio J, Godhinio M, O?Donovan O, Neelam K, et al. Monthly consistency of macular pigment optical density and serum concentrations of lutein and zeaxanthin. Curr Eye Res 2006;31:199-213.
17. Snodderly DM, Handelman GJ, Adler AJ. Distribution of individual macular pigment carotenoids in central retina of macaque and squirrel monkeys. Invest Ophthalmol Vis Sci 1991;32:268-279.
18. Gale CR, Hall NF, Phillips DI, Martyn CN. Plasma antioxidant vitamins and carotenoids and age-related cataract. Ophthalmology 2001;108:1992-1998.
19. Sommerburg O, Keunen JE, Bird AC, van Kuijk FJ. Fruits and vegetables that are sources for lutein and zeaxanthin: the macular pigment in human eyes. Br J Ophthalmol 1998; 82:907-910.
20. Mares-Perlman JA, Brady WE, Klein R, Klein BE, Bowen P, Stacewicz-Sapuntzakis M. Serum antioxidants and agerelated macular degeneration in a population-based case-control study. Arch Ophthalmol 1995;113:1518-1523.
21. Falsini B, Piccardi M, Iarossi G, Fadda A, Merendino E, Valentini P. Influence of short-term antioxidant supplementation on macular function in age-related maculopathy: a pilot study including electrophysiologic assessment. Ophthalmology 2003;110:51-60.
22. Bone RA, Landrum JT, Mayne ST, Gomez CM, Tibor SE, Twaroska EE. Macular pigment in donor eyes with and without AMD: a case-control study. Invest Ophthalmol Vis Sci 2001;42:235-240.
23. Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 1994;272:1413-1420.
24. Beatty S, Boulton M, Henson D, Koh HH, Murray IJ. Macular pigment and age related macular degeneration. Br J Ophthalmol 1999;83:867-877.
25. Aleman TS, Duncan JL, Bieber ML, de Castro E, Marks DA, Gardner LM, et al. Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome. Invest Ophthalmol Vis Sci 2001;42:1873-1881.
26. Landrum JT, Bone RA, Joa H, Kilburn MD, Moore LL, Sprague KE. An one year study of the macular pigment: the effect of 140 days of a lutein supplement. Exp Eye Res 1997;65:57-62.
27. Sousa-Martins D, Maia M, Moraes M, Lima-Filho AA, Rodrigues EB, Chen J, et al. Use of Lutein and Zeaxanthin alone or combined with brilliant blue to identify intraocular structures intraoperatively. Retina 2012;32:1328-1336.
28. Maia M, Furlani BA, Souza-Lima AA, Martins DS, Navarro RM, Belfort Jr R. LUTEIN: a new dye for chromovitrectomy. Retina 2014;34:262-272.
29. Caseli L, Sousa-Martins D, Maia M, Lima-Filho AA, Rodrigues EB, Belfort Jr R. An intraocular dye solution based on lutein and zeaxanthin in a surrogate internal limiting membrane model: a Langmuir monolayer study. Colloids Surf B Biointerfaces 2013;107:124-129.
30. Baszkin A. Molecular recognition on the supported and on the air/water interface-spread protein monolayers. Adv Colloid Interface Sci 2006;128-130:111-120.
31. Pavinatto FJ, Caseli L, Oliveira ON. Chitosan in nanostructured thin films. Biomacromolecules 2010;11: 1897-1908.
32. Toropainen E, Ranta VP, Talvitie A, Suhonen P, Urtti A. Culture model of human corneal epithelium for prediction of ocular drug absorption. Invest Ophtahlmol Vis Sci 2001; 42:2942-2948.
33. Gillies RJ, Didier N, Denton M. Determination of cell number in monolayer-cultures. Anal Biochem 1986;159: 109-113.
34. Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A, McBee W, et al. AREDS 2 Research Group. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology 2012;119:2282-2289.
35. Steel DH, Charles S. Vitrectomy fluidics. Ophthalmologica 2011;226:27-35.
36. Lo HM, Tsai YJ, Du WY, Tsou CJ, Wu WB. A naturally occurring carotenoid, lutein, reduces PDGF and H2O2 signaling and compromised migration in cultured vascular smooth muscle cells. J Biomed Sci 2012;19:18.
37. Maia M, Penha F, Rodrigues EB, Príncipe A, Dib E, Meyer CH, et al. Effects of subretinal injection of patent blue and trypan blue in rabbits. Curr Eye Res 2007;32:309-317.
38. Sujak A, Gabrielska J, Grudziński W, Borc R, Mazurek P, Gruszecki WI. Lutein and zeaxanthin as protectors of lipid membranes against oxidative damage: the structural aspects. Arch Biochem Biophys 1999;371:301-307.
39. Margrain T, Boulton M, Marshall J, Sliney DH. Do blue light filters confer protection against age-related macular degeneration? Prog Retin Eye Res 2004;23:523-531.